Overview
Syvento is a biotechnology company that offers development and formulation services for lipid-based nanocarriers and LNP technology. It specializes in creating lipid-based formulations for pharmaceutical products, including RNA-based drug products. The company provides solutions for encapsulating and delivering therapeutic molecules such as small molecules, RNA, DNA, and proteins.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
SyVento Supports BioResearch Pharma Therapy Program Through Phase I Manufacturing
We are delighted to inform that our ongoing manufacturing partnership with BioResearch Pharma (BRP), supporting the development and production of BRP-007 (psoriasis), moved to the next phase of the technical batch production. BRP is a company developing novel topical dermatological therapies based on repurposing of known and market-authorized active substances. The collaboration between companies covers […]
SyVento Partners with nCode to Deliver a Smarter End-to-End Workflow for mRNA Therapeutic Development
SyVento BioTech is pleased to announce a strategic partnership with nCode, a company specializing in AI-driven mRNA sequence optimization and computational design. Together, we offer biotech and pharmaceutical innovators a more integrated development pathway, from optimized mRNA/LNP design to clinical-ready drug product manufacturing. Complementary Expertise Across the Development Process The partnership combines two highly specialized […]
SyVento Biotech Partners with Biotechna for siRNA/LNP Onco Therapeutics Program
Biotechna and SyVento Biotech entered into a strategic partnership for project „Design and development of nanoparticle RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids”. The project is funded by grant from Medical Research Agency (Agencja Badań Medycznych – ABM; ABM/2022/6). […]
Pharmaceutical Sovereignty Is National Security
Interview with Tomasz Piec, Chairman of the Supervisory Board of SyVento BioTech The COVID-19 pandemic, geopolitical instability and disruptions to global supply chains have fundamentally changed the way we think about security. Alongside defence, energy and cybersecurity, biotechnology is increasingly recognised as a strategic capability. Why could the ability to develop and manufacture medicines become […]
Syvento at EUROBIOTECH 2026: Driving the Conversation on the Future of Polish Biotechnology
We are pleased to announce that Syvento will participate in the 10th Central European Congress of Life Sciences – EUROBIOTECH 2026, one of the leading biotechnology and life sciences events in Central Europe. Taking place on 2–3 July 2026 in Kraków, the anniversary edition of the congress will bring together scientists, biotechnology companies, industry leaders, […]
SyVento BioTech at BIO 2026: Building Partnerships That Accelerate Innovation
BIO International Convention 2026 brings together the global biotechnology community to explore new scientific breakthroughs, strategic partnerships, and opportunities that shape the future of healthcare. This year, SyVento BioTech will join industry leaders in San Diego to connect with biotech innovators, pharmaceutical companies, investors, and technology partners seeking to accelerate the development and commercialization of […]
Industry
Bank accounts
Registered as a VAT taxpayer on 2017-05-09. Active
05 1090 1652 0000 0001 3419 3058
09 1240 6292 1111 0010 9519 6300- 17 1240 6292 1787 0010 9519 6209
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Mar 17, 2021 | Transformation registered |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations of will on behalf of the company are made and documents are signed by the member of the management board. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will and sign documents on behalf of the company.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ms Galleon Gmbh | 30,000 | $486,223.66 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Michał Andrzej Sołowow (64)  | Michał sołowow posiada 100% udziałów w ms galleon gmbh z siedzibą w wiedniu, która posiada 100% udziałów w spółce syvento sp. z o.o. z siedzibą w skawinie. |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | ||
| Aslab ScienceP.S.A. | $1,504,132.17 | aslabsci.com | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| Ecoverseasp. z o.o. | $891,022.45 | coslab.pl | ||
| BioceltixS.A. | $616,315.97 | bioceltix.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| VET Cell Techsp. z o.o. | $483,439.81 | vetcelltech.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-06-05 | Address change (Ul. Chemików 1, 32-600, Oświęcim → Ul. Za Górą 19, 32-050, Skawina) | |
| 2021-07-15 | Share capital change (1,500,000.00 PLN → 1,800,000.00 PLN) | |
| 2021-03-01 | Entered in the register |
FAQ
Last updated: 2026-07-16